Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol. Definitely. I don't know who it was meant for, but its definitely code
I emailed for more clarity on wether the study was in process or the recruitment..now we wait.
Dear Sir/Ms
I apologise this mail was not an answer to your mail. My mistake . As to your question there were some technical delays and it is in process.
M. Bignitz
On 25 Jul 2017, at 20:21, g <g@aol.com> wrote:
Below is the google translation, I'm sure you would be as confused as I...kindly respond in English
"Amiritzik answered her sausages. Just an example of many"
So here wad googles translation..
"Amiritzik answered her sausages. Just an example of many"
Quite interesting...i emailed him back to translate
Yes, i copied and pasted but it came out as question marks
Maybe someone here can translate?
??????? ???? ????????. ??? ?? ????? ???? ????
Mordechai Bignitz
Chairman & CEO
OWC Pharmaceutical Research Corp.
Email: mordechai.bignitz@owcpharma.com
Mordechai bignitz just responded but it is in hebrew..strange considering my email was in English. I will have to get someone to translate and get back to you guys
Oh yes, he clearly wanted to push me over to someone else to answer, as he told me to email through the website ..the conversation didnt leave me feeling warm and fuzzy. At first he almost sounded confused. I'm not sure if it was because of english or i the question was out a shock
Definitely
I'll be happy to hear that, but i just need that info from them. If that were to be the case, we won't have to wait months for news, rather days
I just called the number listed by owcp contacts and location on the clinicaltrials website and spoke to alon sinai, the COO of owcp. I asked him about the study and why the clinical trials website shows not open for recruitment if it was supposed to be completed in july. He said he couldn't talk about anything over the phone and that i should email. Which i already had, but will do again. If i don't receive a response, i will call him back. I want answers.
Yup, time to LOAD up
Oh i thought you meant it as a positive thing that news is in the imminent future
Great, so they can still release an 8k any day with phase 1 results:)
You sound pretty certain...fact or opinion?
Hmmm maybe the results will come out before it gets published. Unless "published" means making public?
https://clinicaltrials.gov/ct2/show/study/NCT02976779#contacts
Phase 1 study was supposed to be completed by July. Although it says not open yet for volunteers, do you guys think they have volunteers and have been conducting this study?
Proof...
Somebody buy "SO we dont close in red"
I agree that Mann buying might not be as significant as ppl like to beleive. I really HOPE his buying is not to mislead us. I am confused by your statement that a board member knew the contents of your email with IR. How do you figure that? Did the board member post something exclusively said to you, that you had not posted?
Lol! I-got it
I would rather you said "i know this will give us multibaggers" ;)
Why do you beleive that what they had worked?
I think things will be fine too. The question is whether i want to be a long term invester and not care that i already lost half my investment. Or reinvest when it drops, which, without news in the very near future, i dont see why it wont.
I know that. I didnt know Whether you were right or wrong in your assessment, because i can't read charts, but my i sensed that you were sincere and lacked ulterior motives.
Bottom line is, what they had wasn't working, and during that time I'm wondering if the president was buying since so much belief is placed on that. Now we have to hope that the updated one works, BUT we really have no clue
It might be the same argument, with the same motives, which everyone decided they figured out, BUT is this, and has this, been going up or down
Joe, it doesnt sound like it is a guess...
I find this price and trading action very strange as well. News is imminent, why would anyone sell now? Unless those sellers dont beleive news will be good?
I'm thinking.. if the company initially thought it would take about 3 months for preclinical trials but then got distracted by updating the technology, now that that is taken care of we should have results this quarter.
Although it SEEMS like a positive that he is buying, we do not know weather it is nefarious or not. What about their financials do you think will look good?
If i remember what u have read in the past, they filed 7 (?) Patents and have 1 granted
Biel has been going up and down from 6 to 8 for weeks
Agreed. I posted it the second i got it withought having looked at the board.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): July 1, 2017
OWC PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
Commission File No.: 0-54856
Delaware 98-0573566
(State of Incorporation)
(I.R.S. Employer Identification No.)
30 Shacham Street. P.O.B. 8324 Petach Tikva, Israel 4918103(Address of Principal Executive Offices) (ZIP Code)
Registrant’s Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 1, 2017, OWC Pharmaceutical Research Corp. (the “Registrant”) appointed Mr. Yossi Dagan as Chief Financial Officer of the Registrant and its wholly-owned Israeli subsidiary, One World Cannabis Ltd.
Yossi Dagan, age 42, Chief Financial Officer: Mr. Dagan is a Certified Public Accountant. From 2015 to present, Mr. Dagan has served as CFO of Top Image Systems Ltd (NASDAQ: TISA), a reporting company under the Securities Exchange Act of 1934 organized under the laws of Israel. TISA is a global company that employs 220 employees, principally in the US, Israel, Germany, UK, Singapore, Japan and Brazil. Prior to his position as CFO of TISA, Mr. Dagan served as VP of Finance at Kenshoo, an Israeli based global SaaS company employing 600 employees. At Kenshoo, Yossi was responsible for all aspects of Finance, including leading the financial planning and analysis team through a $100 million budget preparation which included revenue modeling, forecasting and application of other economic models. Prior to Kenshoo, Mr. Dagan served as Corporate Controller at Imperva Inc. (NYSE: IMPV), a leading provider of cyber security solutions in the cloud and on premises that protect business-critical data and applications. At Imperva, he was responsible for all accounting, tax and treasury operations and was centrally involved in the company moving from an early stage start-up through an IPO to become a successful global public company. Prior to Imperva, Mr. Dagan was a manager at PriceWaterhouseCoopers. He holds a CPA and a BA in Accounting and Business from The College of Management.
Mr. Dagan began his accounting career at PriceWaterhouseCoopers in Israel in 2003, received his degree as a Certified Public Accountant in Israel in 2005 and received his Bachelor of Business degree with a major in accounting in 2003 from The College of Management, Rishon Le’Zion, Israel.
SIGNATURE
OWC Pharmaceutical Research Corp. By:/s/ Mordechai Bignitz Name:Mordechai Bignitz Title:Chief Executive Officer
Date: July 3, 2017
Definitely risk vs. Reward. I took the risk and so far no reward, now i have to make a decision
Joe, they are doing the research...shouldnt they know if it is an unrealistic time frame.. and to delay twice? What have they come through on? I'm not sure why you trust them so much, i wish i had your faith
Disclaimer: i did not sell. But i beg to differ, their shareholder update just made excuses as to why they havent delivered
In theory, what they have is an investors dream. But, can we trust them??